Delivery Order SPE2DB22D2211-SPE2DB25FSFJB
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,438.08 for methylphenidate ER 36 mg tablets (100-count supply) on July 22, 2025, with ultimate completion by July 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,073.04 to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100-count units). This order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed-price, competitively awarded contract with no set-aside designation. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,186.76 for Methylphenidate ER 36 mg tablets (100-count) on August 1, 2025, with completion scheduled for August 4, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside designations and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The pharmaceutical product supports federal medical supply requirements, primarily serving military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100 count) with a ceiling value of $2,501.99. This competitive, non-set-aside award was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,471.36 delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 18 mg tablets (100-count) on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the vendor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,690.77 to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 54 mg tablets (100-count bottles) on July 30, 2025, with completion scheduled for July 31, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,296.30 delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100-count bottles) with an ultimate completion date of July 1, 2025. This is a firm fixed-price, non-set-aside contract issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement running through December 2026. The product will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency (DLA) awarded a $1,479.44 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Methylphenidate ER 36 mg tablets in a quantity of 100 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,448.52 to supply Methylphenidate ER 36 mg tablets (100-count units) with an ultimate completion date of August 19, 2025. The contract is classified as a non-set-aside, competitively awarded delivery order with firm fixed pricing. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,484.38 to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100 count) on August 7, 2025, with completion expected by August 8, 2025. This firm fixed price, non-set-aside delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply needs, particularly for...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSFJBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,304.90 to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100-count bottles), with a completion date of September 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The place of performance is located at the contractor's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a prime vendor for federal pharmaceutical procurement, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply medications and medical supplies to military healthcare programs and other federal customers, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains through open competition and firm fixed-price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/19/25 |